Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

• Status: WITHDRAWN
• Trial end date: 2024-10-21

Summary

To learn if MT-0169 is safe to give to patients with AML or T-ALL. The effects of this drug will also be studied.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center